Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 and Polymyxin B Pharmacokinetics in Healthy Volunteers
NCT07580586Phase 1Recruiting
- Sponsor
- BioVersys AG
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BV100 in Acinetobacter baumannii infection (2 arms), sponsored by BioVersys AG. Primary endpoint: Pharmacokinetics of polymyxin B at 96 hours. Started Mar 2026; status: recruiting.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT07580586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580586.